Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BMS-646256 in Overweight/Obese T2D Patients
NCT00541567Phase 3Withdrawn
- Sponsor
- Solvay
- Start
- Mar 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ibipinabant in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Solvay. Primary endpoints: Absolute change from baseline in body weight at 26 weeks and Absolute change from baseline in HbA1c at 26 weeks. Planned start Mar 2008; status: withdrawn.
02
Drugs
ibipinabant
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT00541567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541567.